Epigral Q1 Results FY27: Net Profit Falls 37.9% to Rs 99.7 Crore Despite 16.3% Revenue Growth
- July 27, 2026
- Posted by: Neeraj Pandey
- Category: News
Epigral Q1 results FY27: Net profit Rs 99.7 Cr (-37.9% YoY) despite revenue up 16.3% to Rs 705 Cr. EBITDA margin 25.4% vs 26.9%. Stock at Rs 1,157 (-0.49%) on 27 July.
Key Takeaways
- Epigral’s net profit for Q1 FY27 fell 37.9% to Rs 99.7 crore from Rs 161 crore a year earlier.
- Revenue rose 16.3% year on year to Rs 705 crore from Rs 607 crore, growing even as profit declined.
- EBITDA grew 9.7% to Rs 179 crore, but the EBITDA margin slipped to 25.4% from 26.9%.
- The stock was roughly flat at Rs 1,157 on 27 July 2026, down 0.49%, a muted reaction relative to the size of the profit decline.
Epigral’s Q1 results FY27 net profit fell 37.9% to Rs 99.7 crore for the quarter ended 30 June 2026, down from Rs 161 crore a year earlier, even as revenue grew 16.3% to Rs 705 crore. This is an unusual combination: double-digit revenue growth paired with a sharp profit decline, which points to cost pressures or below-the-EBITDA-line items weighing on the bottom line. This article breaks down the Epigral Q1 results FY27 in detail and explains why profit fell even as the business grew its topline.
Prepared by Kunal Singla, Associate Director at Univest, this review of the Epigral Q1 results FY27 is based on the company’s consolidated exchange filing for the June 2026 quarter.
Click Here – Get Free Investment Predictions
Epigral Q1 Results FY27: Key Numbers at a Glance
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 705 Cr | Rs 607 Cr | +16.3% |
| EBITDA | Rs 179 Cr | Rs 163 Cr | +9.7% |
| EBITDA Margin | 25.4% | 26.9% | Down |
| Net Profit | Rs 99.7 Cr | Rs 161 Cr | -37.9% |
All figures in the Epigral Q1 results FY27 table above are on a consolidated basis for the quarter ended 30 June 2026, compared with Q1 FY26.
Epigral Q1 Results FY27: Revenue Grows 16.3%
Revenue in the Epigral Q1 results FY27 rose 16.3% year on year to Rs 705 crore from Rs 607 crore. As a specialty chemicals manufacturer, Epigral’s topline growth this quarter points to healthy volume or realisation gains in its core chloro-chemicals and specialty chemicals segments.
Epigral Q1 Results FY27: Why Net Profit Fell 37.9% Despite Revenue Growth
Epigral’s net profit fell 37.9% to Rs 99.7 crore in Q1 FY27, even though revenue rose 16.3% and EBITDA grew 9.7% to Rs 179 crore. The gap between EBITDA growth and the sharp profit decline means the pressure came from below the operating line, most likely from higher depreciation, interest costs on expanded capacity, or a lower base of other income and exceptional gains in the year-ago quarter.
The EBITDA margin itself slipped only modestly, to 25.4% from 26.9%, which confirms that the operating business held up reasonably well; the outsized profit decline is a below-EBITDA-line story that investors should probe closely in the detailed results.
Epigral Q1 Results FY27: EBITDA Still Grows
EBITDA for the quarter grew 9.7% to Rs 179 crore from Rs 163 crore, a healthier trend than the net profit line suggests. This divergence is the single most important thing to understand about the Epigral Q1 results FY27.
Investors should treat the EBITDA growth, not the net profit decline, as the better proxy for how Epigral’s core specialty chemicals business actually performed this quarter, while investigating the specific below-the-line items that dragged on the bottom line.
Talk to a SEBI Registered Investment Adviser Before You Invest
Stock Price Reaction to the Epigral Q1 Results FY27
Epigral shares were largely steady at Rs 1,157 on 27 July 2026, down just 0.49%. Given the scale of the net profit decline, this muted reaction suggests the market had already priced in some earnings softness, or is looking through the profit miss toward the healthier EBITDA and revenue trends.
What the Epigral Q1 Results FY27 Indicate for Investors
The Epigral Q1 results FY27 illustrate why headline net profit numbers alone can be misleading. Revenue and EBITDA both grew this quarter, yet net profit fell sharply, most likely due to one-off items or higher financing and depreciation costs tied to capacity expansion.
Specialty chemicals companies like Epigral often carry elevated depreciation and interest costs during capacity expansion phases, which can depress reported net profit even while the underlying operating business is expanding.
Business Context Behind the Epigral Q1 Results FY27
Epigral operates in the specialty and chloro-chemicals space, and its quarterly numbers sit within a broader industry cycle that shapes how this print should be read. Demand conditions, input costs and the competitive landscape all feed into the reported figures, which is why the Epigral Q1 results FY27 need to be read alongside sector-wide trends rather than in isolation.
It is also worth remembering that quarterly results such as these are unaudited and subject to limited review. Any restatements, exceptional items or accounting changes disclosed in the notes to the Epigral Q1 results FY27 can shift how the reported profit should be interpreted, so reading the full exchange filing alongside this summary is always worthwhile.
Key Things to Watch After the Epigral Q1 Results FY27
- Below-the-line items: Management’s explanation for the gap between EBITDA growth and the net profit decline this quarter.
- Capacity utilisation: Whether new capacity additions are ramping up as expected, supporting the revenue growth seen this quarter.
- Interest and depreciation costs: Trends in financing costs as the company’s expansion capex is absorbed into the balance sheet.
- Margin trajectory: Whether the EBITDA margin recovers toward the 26.9% level seen a year earlier.
Download the Univest iOS App or Univest Android App to track quarterly results, live prices and research updates in one place.
Conclusion
The Epigral Q1 results FY27 show net profit falling 37.9% to Rs 99.7 crore even as revenue grew 16.3% to Rs 705 crore and EBITDA rose 9.7%. The disconnect between operating performance and the bottom line is the key issue investors should investigate. As Kunal Singla notes, understanding the below-the-line drivers is essential before drawing conclusions, and investors should consult a SEBI registered investment adviser before acting on these results.
Disclaimer: This article is for educational and informational purposes only and should not be considered investment advice. Figures are sourced from the company’s exchange filings for the quarter ended 30 June 2026. Stock market investments are subject to risks. Please consult a SEBI registered investment adviser before making any investment decision. Univest Research Analyst SEBI Registration No. INH000013776.
FAQs on Epigral Q1 Results FY27
What was Epigral’s net profit in Q1 results FY27?
Ans. Epigral’s net profit in Q1 results FY27 fell 37.9% to Rs 99.7 crore from Rs 161 crore a year earlier.
What was Epigral’s revenue in Q1 FY27?
Ans. Revenue in Epigral’s Q1 results FY27 rose 16.3% to Rs 705 crore from Rs 607 crore.
Why did Epigral’s net profit fall despite revenue growth?
Ans. Epigral’s net profit fell in Q1 results FY27 despite revenue and EBITDA growth, pointing to higher depreciation, interest costs or a weaker base of other income below the operating line.
What was Epigral’s EBITDA in Q1 FY27?
Ans. Epigral’s EBITDA in Q1 results FY27 grew 9.7% to Rs 179 crore from Rs 163 crore, with margin at 25.4% versus 26.9% a year earlier.
How did Epigral shares react to the Q1 results FY27?
Ans. Epigral shares were largely flat at Rs 1,157 on 27 July 2026, down 0.49% following the Q1 results FY27.
Were the Epigral Q1 results FY27 consolidated?
Ans. Yes, the Epigral Q1 results FY27 discussed here are on a consolidated basis for the quarter ended 30 June 2026.
What should investors watch after Epigral’s Q1 results FY27?
Ans. Investors should watch management’s explanation for the profit decline, capacity utilisation, financing costs, and the EBITDA margin trajectory.
Are the Epigral Q1 results FY27 a buy signal?
Ans. Quarterly results are a data point, not a recommendation. Investors should assess valuations and their own risk profile, and consult a SEBI registered investment adviser before investing.
